[Hypertensive zoster iritis].
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Two patients with cutaneous malignant melanoma, vitiligo, and uveitis are described. The occurrence of vitiligo following cutaneous melanoma is not uncommon and has been interpreted to result from cellular and humoral factors directed against melanoma cells that also destroy normal cutaneous melanocytes. The present cases raise the possibility that melanocytes in the eye as well as the skin may be affected.
Rat eyes pretreated with 10 microL of topically applied indoxole or 14C-indomethacin, both drugs as 0.5%, 1.0%, and 2.0% solutions in polysorbate 80, were subjected 60 minutes later to an intravitreal injection of 5 microL of 5.0% sodium arachidonate. Following a 30-minute interval, the iris vascular pattern was photographed under the same standardized conditions as in the preinjection control photographs. Comparison of the average diameters of preselected vessels showed indoxole to be more effective than indomethacin in inhibition of iris vascular dilation at all concentrations tested. Intracameral unbound indomethacin concentration was a whole order higher than that of indoxole after comparable doses. The difference in relative effect of the two drugs is neither a function of aqueous concentration nor of aqueous protein binding.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.